Psychiatric Times
CONTINUE TO SITE

OR WAIT null SECS

Psychiatric Times
Spotlight
Commentary
Cultural Corner
Psychiatric Practice
Series
Topics
Media
Publications
Job BoardCME/CEPartners
Resources
Subscribe

  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Psychiatric Times. All rights reserved.

SpotlightSee All >
  • Psychedelics
  • ADHD
  • APA Conference Insider
  • Case Discussion with Dr. Moukaddam: Bipolar Disorder
  • Major Depressive Disorder
CommentarySee All >
  • Couch In Crisis
  • Early Career Psychiatry
  • History of Psychiatry
  • Residents Corner
Cultural CornerSee All >
  • Film and Book Reviews
  • Poetry
  • Writers Contest
Psychiatric PracticeSee All >
  • Burnout
  • Careers
  • Coding
  • Guidelines
  • Risk Management
  • Telepsychiatry
SeriesSee All >
  • Climate Change
  • Critical Conversations in Psychiatry
  • Portraits
  • Psychiatric Views on the Daily News
  • Tales From the Clinic: The Art of Psychiatry
  • Tales from the New Asylum
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Psychiatric Times. All rights reserved.

EP 1: Using Naloxone Against Opioid Use

March 8th 2022

Our panel of doctors and pharmacists introduce naloxone, an opioid antagonist, as an option when treating opioid abuse or overdose.